Partnership explores using HDL as a tool for delivering drugs

By Jan Jarvis

Andras Lacko, PhD researches HDL Drug Delivery
 
UNT Health Science Center has joined with the international biopharmaceutical company Cerenis Therapeutics to develop HDL-based drug delivery systems for treating cardiovascular and metabolic diseases.

The joint strategic partnership called the “HDL Drug Delivery Initiative” will leverage the expertise of the research team led by Andras Lacko, PhD, Professor of Physiology and Anatomy at UNT Health Science Center, with the France-based company Cerenis Therapeutics.

The “HDL Drug Delivery Initiative” will focus on developing new strategies to address difficult-to treat-patients by creating a unique HDL platform technology for drug delivery.

“Our collaboration will focus on the development of new drug delivery systems based on HDL in order to deliver pharmaceutically active ingredients to specifically targeted cells,” Dr. Lacko said. “Cerenis is well positioned to move forward into immune-oncology and chemotherapeutic drug delivery to become a leading targeted HDL drug delivery company.”

Cerenis is delighted to work with Dr. Lacko and UNT Health Science Center, said Jean-Louis Dasseux, CEO of Cerenis Therapeutics.

“This partnership will focus on innovative solutions for the HDL drug delivery market,” he said. “It is an important step forward for our technology development program and our nanotechnology platform as we look forward to building a strong integrated relationship beneficial for both parties.”

Dr. Lacko’s research has long focused on the use of nanoparticles to deliver anti-cancer drugs directly to tumors while avoiding damage to healthy cells to spare patients the harmful side effects of chemotherapy.

HDL particles, loaded with an active agent, hold the promise to target and selectively kill malignant cells while sparing healthy ones. A wide variety of drugs can be embedded in these particles targeting markers specific to cancer cells and bring these potent drugs to their intended site of action, with lowered systemic toxicity.

As part of the agreement, Dr. Lacko’s research group will conduct early preclinical research activities related to the development of new drug complexes based on HDL platforms. This work will include developing further understanding of the properties relevant to creating an HDL-based carrier and developing new strategies to trap biologically active molecules within HDL.

The strategic partnership with Dr. Lacko represents another marker of Cerenis’ evolution into a company with novel HDL platforms for drug delivery. Cerenis will lead the advanced preclinical research activities, related to development of new HDL based drug complexes. Cerenis will be responsible for future clinical developments as well.

CERENIS Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative lipid metabolism therapies for the treatment of cardiovascular, metabolic diseases, and HDL targeted drug delivery platform technologies.

HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids are removed from arteries and transported to the liver for elimination from the body.


Read the news release from Cerenis and UNTHSC:

CERENIS Therapeutics and University of North Texas Health Science Center announce a strategic initiative to develop new HDL-based pharmaceutical products

Recent News

Apta Group Shot
  • Community
|Dec 20, 2024

CHP hosts geriatric physical therapy certification course

In the past year, the Department of Physical Therapy at The University of North Texas Health Science Center at Fort Worth hosted both a hybrid and a traditional certification course in geriatric exercise, showcasing its commitment to improving the quality of life for aging adults through physical th...
Mha Winning Case Study Students Img 7151
  • Community
|Dec 19, 2024

MHA students take home top prize at case competition

A Master of Health Administration student team at The University of North Texas Health Science Center at Fort Worth recently won first place at the 2024 American College of Healthcare Executives North Texas Chapter’s student case study competition. Winning students Darshan Amin, Philip “PJ” H...
Miranda
  • Community
|Dec 18, 2024

PT students explore disability through art

On the second floor of the EAD building at The University of North Texas Health Science Center at Fort Worth, a collection of 50 pieces of art told powerful, deeply personal stories of resilience and humanity. Each piece, crafted by first-year physical therapy students, represented the journey o...
Img 7828
  • Community
|Dec 16, 2024

TCOM student gives presentation at NAPCRG International Conference

It was a rare and prestigious accomplishment for Texas College of Osteopathic Medicine student Rebecca Modisette who became the first medical student from TCOM to give an oral presentation at the world-renowned North American Primary Care Research Group’s 52nd annual meeting in Quebec City, Canada...